AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30610026 — intervention group
Group type: COMPARATOR
Intervention: Warm ischaemia (no renal hypothermia)
Number of subjects: 0
Study 29395637 — intervention group
Group type: EXPERIMENTAL
Intervention: D + Ca + B (1200 IE vitamin D3, 800 mg Ca-carbonate, 0.5 mg B9, 50 mg B6, 0.5 mg B12)
Number of subjects: 63
Study 29395637 — intervention group
Group type: COMPARATOR
Intervention: D + Ca (1200 IE vitamin D3, 800 mg Ca-carbonate)
Number of subjects: 63
Study 26294207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin (Por‐8, Ferring) solution
Number of subjects: 80
Study 26294207 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study 24500582 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar eversion
Number of subjects: 68
Study 24500582 — intervention group
Group type: COMPARATOR
Intervention: Patellar subluxation
Number of subjects: 68
Study 23082707 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpermin (peppermint oil capsules)
Number of subjects: 65
Study 23082707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 20102596 — intervention group
Group type: EXPERIMENTAL
Intervention: McKenzie method in addition to first-line care (advice, reassurance, and time-contingent acetaminophen)
Number of subjects: 148
Study 20102596 — intervention group
Group type: COMPARATOR
Intervention: First-line care alone
Number of subjects: 148
Study 18094892 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised pelvic floor muscle exercises
Number of subjects: 44
Study 18094892 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised pelvic floor muscle exercises
Number of subjects: 44
Study 15322767 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM (Statistical Parametric Mapping)
Number of subjects: 20
Study 15322767 — intervention group
Group type: EXPERIMENTAL
Intervention: NS (NEUROSTAT)
Number of subjects: 20
Study 12163810 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rhAPC)
Number of subjects: 0
Study 10502624 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch based hot stage extrusion formulation containing 300 mg anhydrous theophylline
Number of subjects: 8
Study 10502624 — intervention group
Group type: COMPARATOR
Intervention: Commercially available multiple unit sustained release product
Number of subjects: 8
Study 8604729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol solution (administered twice daily)
Number of subjects: 42
Study 8604729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol gellan (administered once daily)
Number of subjects: 42
Study 8604729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 1916557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcit (aluminium‐magnesium hydroxide carbonate hydrate)
Number of subjects: 0
Study 1916557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6276746 — intervention group
Group type: COMPARATOR
Intervention: Calcium (with or without vitamin D)
Number of subjects: 165
Study 6276746 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride combined with conventional therapy
Number of subjects: 165
Study 6276746 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen and calcium (with or without vitamin D)
Number of subjects: 165
Study 6276746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride, estrogen, and calcium (with or without vitamin D)
Number of subjects: 165
Study 6276746 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride (one year of treatment)
Number of subjects: 165
Study 6276746 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium, fluoride, and estrogen
Number of subjects: 165
Study 31138725 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 50 mg/m2, Oxaliplatin 85 mg/m2, 5-FU 2400 mg/m2 continuous intravenous infusion over 46 hours, cycles every 2 weeks
Number of subjects: 44
Study 27546475 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective blankets
Number of subjects: 50
Study 27546475 — intervention group
Group type: COMPARATOR
Intervention: Forced air warming devices
Number of subjects: 50
Study 27554525 — intervention group
Group type: EXPERIMENTAL
Intervention: KNW self-management intervention
Number of subjects: 231
Study 27554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Module referral advice
Number of subjects: 231
Study 27554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a partner
Number of subjects: 231
Study 27554525 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived personal relevance
Number of subjects: 231
Study 24445878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia (target mean arterial pressure of 50 mm Hg)
Number of subjects: 100
Study 24445878 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia (target mean arterial pressure of 60 mm Hg)
Number of subjects: 100
Study 24445878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anesthesia
Number of subjects: 100
Study 24445878 — intervention group
Group type: COMPARATOR
Intervention: Standard anesthesia
Number of subjects: 100
Study 22805107 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice (140 ml, 8.7 mmol NO3‐)
Number of subjects: 20
Study 22805107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate‐depleted beetroot juice)
Number of subjects: 20
Study 19922893 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of imatinib 400 mg
Number of subjects: 30
Study 19922893 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of imatinib 400 mg
Number of subjects: 30
Study 19922893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study 17876497 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 500 IU/kg/day for three days
Number of subjects: 73
Study 17876497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15606396 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP870 10 mg/kg
Number of subjects: 92
Study 15606396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 15606396 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP870 5 mg/kg
Number of subjects: 92
Study 15606396 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP870 20 mg/kg
Number of subjects: 92
Study 11125881 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir and one protease inhibitor
Number of subjects: 71
Study 9032837 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0
Study 9032837 — intervention group
Group type: COMPARATOR
Intervention: Conventional cholecystectomy
Number of subjects: 0
Study 7964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin seeds snack
Number of subjects: 0
Study 7964254 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal mixture
Number of subjects: 0
Study 7964254 — intervention group
Group type: COMPARATOR
Intervention: Control period
Number of subjects: 0
Study 3456942 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical prostaglandin E2 (PGE2) gel
Number of subjects: 76
Study 3456942 — intervention group
Group type: COMPARATOR
Intervention: Intraamniotic prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 76
Study 3180669 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 37
Study 3180669 — intervention group
Group type: COMPARATOR
Intervention: sodium iothalamate
Number of subjects: 37
Study 31046812 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with anterior inclination of 5%
Number of subjects: 36
Study 31046812 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training with anterior inclination of 10%
Number of subjects: 36
Study 31046812 — intervention group
Group type: COMPARATOR
Intervention: Treadmill gait training without inclination (control group)
Number of subjects: 36
Study 28460259 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40mg SQ daily
Number of subjects: 91
Study 28460259 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 60mg SQ daily
Number of subjects: 91
Study 28460259 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 91
Study 26291847 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 164
Study 26291847 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study 23273888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 25mg/5 days
Number of subjects: 114
Study 23273888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 100mg/2 days
Number of subjects: 114
Study 23273888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 100mg/5 days
Number of subjects: 114
Study 23273888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 21519928 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 64
Study 21519928 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 64
Study 17673219 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 134
Study 17673219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 17673219 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10-80 mg/day)
Number of subjects: 134
Study 17673219 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin-Placebo group
Number of subjects: 134
Study 17673219 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 134
Study 17268397 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 17268397 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 12604544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day treatment with 2 g of valacyclovir twice daily for 1 day
Number of subjects: 0
Study 12604544 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day treatment with 2 g of valacyclovir twice daily for 1 day and then 1 g of valacyclovir twice daily for 1 day
Number of subjects: 0
Study 12604544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12604544 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (both treatment regimens)
Number of subjects: 0
Study 10618555 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention targeting depression and/or low social support
Number of subjects: 3000
Study 10618555 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group not explicitly mentioned)
Number of subjects: 3000
Study 9366460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.3% and 0.60%)
Number of subjects: 12
Study 9366460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (15% and 30%)
Number of subjects: 12
Study 9366460 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 12
Study 1555557 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged exercise (trained limb)
Number of subjects: 20
Study 1555557 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged exercise (untrained limb)
Number of subjects: 20
Study 1555557 — intervention group
Group type: COMPARATOR
Intervention: Control limbs
Number of subjects: 20
Study 1555557 — intervention group
Group type: EXPERIMENTAL
Intervention: Untrained limb
Number of subjects: 20
Study 1555557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained limb
Number of subjects: 20
Study 3982804 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (Van Lint eyelid block and superior rectus bridle suture)
Number of subjects: 0
Study 3982804 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (Nadbath block and episcleral retraction suture)
Number of subjects: 0
Study 3982804 — intervention group
Group type: COMPARATOR
Intervention: Group B (Van Lint block and episcleral retraction suture)
Number of subjects: 0
Study 3982804 — intervention group
Group type: COMPARATOR
Intervention: Group C (Nadbath retroauricular facial nerve block and superior rectus bridle suture)
Number of subjects: 0
Study 29860335 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine 3300 mg orally twice daily for 10 days, then 4950 mg twice daily for 12 weeks
Number of subjects: 27
Study 29860335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 27789938 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Empowerment Intervention for Stroke Self‐management (HEISS)
Number of subjects: 210
Study 27789938 — intervention group
Group type: COMPARATOR
Intervention: Usual ambulatory rehabilitation care (Control Group)
Number of subjects: 210
Study 24665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment for 4 weeks
Number of subjects: 14
Study 24665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus methotrexate
Number of subjects: 14
Study 24665995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 14
Study 22586173 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 456
Study 22586173 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 456
Study 19683399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg cortisol (hydrocortisone)
Number of subjects: 39
Study 19683399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18654733 — intervention group
Group type: EXPERIMENTAL
Intervention: External Qigong Therapy (EQT)
Number of subjects: 112
Study 18654733 — intervention group
Group type: COMPARATOR
Intervention: Sham Treatment (Control)
Number of subjects: 112
Study 18654733 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (EQT and Control)
Number of subjects: 112
Study 16309707 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety hall combined with mandatory skid training
Number of subjects: 1326
Study 16309707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no safety hall training)
Number of subjects: 1326
Study 12494034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day) for 1 month
Number of subjects: 30
Study 12494034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg/day) in 5 patients
Number of subjects: 30
Study 11097601 — intervention group
Group type: COMPARATOR
Intervention: Control group (fewer than 15 small drusen)
Number of subjects: 4519
Study 11097601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate drusen, extensive small drusen, or pigment abnormalities (group 2)
Number of subjects: 4519
Study 11097601 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more large drusen or extensive intermediate drusen (group 3)
Number of subjects: 4519
Study 11097601 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovascular AMD (group 5)
Number of subjects: 4519
Study 11097601 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy (group 4)
Number of subjects: 4519
Study 8647493 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher amount of cholesterol in red cell membranes
Number of subjects: 24
Study 8647493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol amount in red cell membranes
Number of subjects: 24
Study 1286739 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 10
Study 1286739 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 10
Study 3782679 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of 0.5 mg epinephrine
Number of subjects: 0
Study 3782679 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 1.5 to 4.5 mg epinephrine (10 to 30 inhalations)
Number of subjects: 0
Study 3782679 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 2 to 3 mg epinephrine
Number of subjects: 0
Study 31906814 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training (FRT)
Number of subjects: 38
Study 31906814 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CRT)
Number of subjects: 38
Study 29952122 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital training system with Online Peer‐Review System (OPRS) and Real‐time Dental Training and Evaluation System (RDTES)
Number of subjects: 66
Study 29952122 — intervention group
Group type: COMPARATOR
Intervention: Traditional training method with instructor demonstration and evaluation
Number of subjects: 66
Study 29952122 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital training system
Number of subjects: 66
Study 28784687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study 28784687 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 26254513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 7.5 mg/day
Number of subjects: 0
Study 26254513 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 15 mg/day
Number of subjects: 0
Study 26254513 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg/day
Number of subjects: 0
Study 23644909 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket filling with PRF after simple extraction
Number of subjects: 23
Study 23644909 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket filling with PRF after extraction with mucosal flap
Number of subjects: 23
Study 23644909 — intervention group
Group type: COMPARATOR
Intervention: Control group with simple extraction without socket filling
Number of subjects: 23
Study 21933431 — intervention group
Group type: EXPERIMENTAL
Intervention: Public commitment activities
Number of subjects: 4603
Study 21933431 — intervention group
Group type: EXPERIMENTAL
Intervention: Public commitment activities (overweight or obese subgroup)
Number of subjects: 4603
Study 21933431 — intervention group
Group type: EXPERIMENTAL
Intervention: No public commitment activities
Number of subjects: 4603
Study 18577531 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted educational intervention
Number of subjects: 70
Study 18577531 — intervention group
Group type: COMPARATOR
Intervention: Standard pre-dialysis education
Number of subjects: 70
Study 16902290 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 16
Study 16902290 — intervention group
Group type: COMPARATOR
Intervention: 311-nm UVB phototherapy
Number of subjects: 16
Study 12807341 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Kava LI 150
Number of subjects: 129
Study 12807341 — intervention group
Group type: COMPARATOR
Intervention: 10 mg Buspirone
Number of subjects: 129
Study 12807341 — intervention group
Group type: COMPARATOR
Intervention: 100 mg Opipramol
Number of subjects: 129
Study 10230742 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reminders for redundant tests
Number of subjects: 11586
Study 10230742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 11586
Study 10230742 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effect of reminders
Number of subjects: 11586
Study 8618182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (52 micromol or 50,000 IU orally administered at birth)
Number of subjects: 2067
Study 8618182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2067
Study 8618182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 2067
Study 2016833 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-bonded catheters (pretreated with tridodecylmethylammonium chloride and immersed in a 50-mg/mL cefazolin solution)
Number of subjects: 178
Study 2016833 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard catheters)
Number of subjects: 178
Study 2016833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (antibiotic-bonded and control)
Number of subjects: 178
Study 2016833 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic immersion solutions
Number of subjects: 178
Study 6223151 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (PIPC) administered by intravenous injection or infusion
Number of subjects: 16
Study 30907196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) with two samples
Number of subjects: 806
Study 30907196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) positivity
Number of subjects: 806
Study 30907196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) at cut off levels of 10 µg/g and 20 µg/g
Number of subjects: 806
Study 28438548 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive reading with puppet
Number of subjects: 163
Study 28438548 — intervention group
Group type: COMPARATOR
Intervention: Interactive reading without puppet
Number of subjects: 163
Study 28438548 — intervention group
Group type: COMPARATOR
Intervention: Passive reading with puppet
Number of subjects: 163
Study 28438548 — intervention group
Group type: COMPARATOR
Intervention: Passive reading without puppet
Number of subjects: 163
Study 26393910 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng tea infusion
Number of subjects: 14
Study 26393910 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 14
Study 23415983 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help Manual
Number of subjects: 80
Study 23415983 — intervention group
Group type: COMPARATOR
Intervention: Intention-control
Number of subjects: 80
Study 22115143 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 108
Study 22115143 — intervention group
Group type: COMPARATOR
Intervention: Usual services delivered by youth offending teams (YOT)
Number of subjects: 108
Study 19998453 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative care intervention (PPCC)
Number of subjects: 58
Study 18214192 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc cream
Number of subjects: 50
Study 18214192 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 50
Study 15159321 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month moderate intensity aerobic exercise intervention
Number of subjects: 170
Study 15159321 — intervention group
Group type: COMPARATOR
Intervention: Stretching control group
Number of subjects: 170